O
Oliver Hartmann
Researcher at University of Tokyo
Publications - 89
Citations - 3392
Oliver Hartmann is an academic researcher from University of Tokyo. The author has contributed to research in topics: Medicine & Heart failure. The author has an hindex of 27, co-authored 72 publications receiving 2802 citations.
Papers
More filters
Journal ArticleDOI
Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea : results from the BACH (Biomarkers in Acute Heart Failure) trial
Alan S. Maisel,Christian Mueller,Richard M. Nowak,W. Frank Peacock,Judd W. Landsberg,Piotr Ponikowski,Martin Möckel,Christopher Hogan,Alan H.B. Wu,Mark Richards,Paul Clopton,Gerasimos Filippatos,Salvatore Di Somma,Inder S. Anand,Leong L. Ng,Lori B. Daniels,Sean-Xavier Neath,Robert H. Christenson,Mihael Potocki,James McCord,Garret Terracciano,Dimitrios Th. Kremastinos,Oliver Hartmann,Stephan von Haehling,Andreas Bergmann,Nils G. Morgenthaler,Stefan D. Anker +26 more
TL;DR: MR-proANP is as useful as BNP for AHF diagnosis in dyspneic patients and may provide additional clinical utility when BNP is difficult to interpret, and MR-proADM identifies patients with high 90-day mortality risk and adds prognostic value to BNP.
Journal ArticleDOI
Copeptin improves early diagnosis of acute myocardial infarction.
Till Keller,Stergios Tzikas,Tanja Zeller,Ewa Czyz,Lars Lillpopp,Francisco Ojeda,Alexander Roth,Christoph Bickel,Stephan Baldus,C. Sinning,Philipp S. Wild,Edith Lubos,Edith Lubos,Dirk Peetz,Jan Kunde,Oliver Hartmann,Andreas Bergmann,Felix Post,Karl J. Lackner,Sabine Genth-Zotz,Viviane Nicaud,Laurence Tiret,Thomas Münzel,Stefan Blankenberg +23 more
TL;DR: In triage of chest pain patients, determination of copeptin in addition to troponin improves diagnostic performance, especially early after CPO, and therefore aids in early and safe rule-out of myocardial infarction.
Journal ArticleDOI
C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study.
Adriaan A. Voors,Stephan von Haehling,Stefan D. Anker,Hans L. Hillege,Joachim Struck,Oliver Hartmann,Andreas Bergmann,Iain B. Squire,Dirk J. van Veldhuisen,Kenneth Dickstein +9 more
TL;DR: Copeptin is a strong and novel marker for mortality and morbidity in patients with heart failure after AMI and the predictive value of copeptin was even stronger than BNP and NT-proBNP.
Journal ArticleDOI
Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
TL;DR: All new biomarkers were good predictors of short- and long-term all-cause mortality, superior to inflammatory markers, and at least comparable to CRB-65 score.
Journal ArticleDOI
Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin Secondary Results From the Biomarkers in Acute Heart Failure (BACH) Study
Alan S. Maisel,Yang Xue,Kevin S. Shah,Christian Mueller,Richard Nowak,W. Frank Peacock,Piotr Ponikowski,Martin Möckel,Christopher Hogan,Alan H.B. Wu,Mark Richards,Paul Clopton,Gerasimos Filippatos,Salvatore Di Somma,Inder S. Anand,Leong L. Ng,Lori B. Daniels,Sean-Xavier Neath,Robert H. Christenson,Mihael Potocki,James McCord,Garret Terracciano,Dimitrios Th. Kremastinos,Oliver Hartmann,Stephan von Haehling,Andreas Bergmann,Nils G. Morgenthaler,Stefan D. Anker +27 more
TL;DR: Copeptin was highly prognostic for 90-day adverse events in patients with acute HF, adding prognostic value to clinical predictors, ser um sodium, and natriuretic peptides.